Non-COVID revenue grew by 9 per cent YoY to Rs. 244 crores
Metropolis Healthcare has announced its unaudited consolidated financial results for the third quarter (Q3FY22).
Q3FY22 financial highlights:
- EBITDA margin (Before CSR, ESOP & Onetime acquisition cost): 27.5 per cent
- B2C revenue growth (Non-COVID): +25 per cent YoY
- Reported PAT: Rs 41.2 Crore
Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “During Q3FY22, we are pleased to share that we have been able to grow our non-COVID revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital& marketing, manpower& customer experience initiatives
in order to strengthen our brand. This has impacted margins which we believe is a shortterm phenomenon. Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers. We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.”